Centrica plc announces that it purchased on 27 March 2025 (through Merrill Lynch International) 66,910 Centrica plc ordinary shares of 6 14/81 pence each at a price of 148.73 pence per share. The purchased shares will be held as treasury shares. Such purchase was effected pursuant to the extension of the Company's 2024-25 buyback programme announced on 27 December 2024 and in accordance with the non-discretionary share repurchase agreement entered into with Merrill Lynch International as also announced on 27 December 2024, which agreement was subsequently amended as announced on 3 March 2025.
Since 3 March 2025, Centrica has purchased 25,139,631 ordinary shares at a cost (excluding dealing and associated costs) of £36,778,250.65.
Following the above purchase, Centrica plc holds 456,788,258 ordinary shares in treasury, and has 5,036,318,956 ordinary shares in issue (excluding treasury shares).
In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 (the Market Abuse Regulation) (as in force in the UK and as amended by the Market Abuse (Amendment) (EU Exit) Regulations 2019), detailed information about the individual purchases made by Merrill Lynch International is set out below.
Transaction details: Centrica plc ordinary shares of 6 14/81 pence each
Issuer name:
Centrica plc
ISIN:
GB00B033F229
Intermediary name:
Merrill Lynch International
Intermediary Code:
MLILGB3LESF
Currency:
GBP
Aggregated information
Date of purchase:
27 March 2025
Number of ordinary shares purchased:
66,910
Highest price paid:
149.15p
Lowest price paid:
147.55p
Volume weighted average price paid per share:
148.73p
Disaggregated information
The table attached contains detailed information of the individual trades made byMerrill Lynch International, as part of the buyback programme.
Click on, or paste the following link into your web browser, to view the associated PDF document.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.
